Since adjuvant treatment of early ER+ breast cancer frequently consists of chemotherapy followed by anti-estrogens, most commonly tamoxifen, and in menopausal women an aromatase inhibitor, this therapeutic sequence minimizes the effects of chemotherapy. The gene discussed is CYP19A1; the disease is breast carcinoma.